BioCentury
ARTICLE | Company News

Management tracks

July 5, 2017 11:47 PM UTC

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc. spun out its histone deacetylase (HDAC) assets into Regenacy prior to its acquisition by Celgene Corp. (NASDAQ:CELG).

Dermatology play Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) named David Domzalski CEO. He succeeds Dov Tamarkin, who will become CSO and will remain a director. Domzalski was president of Foamix’s U.S. subsidiary Foamix Pharmaceuticals Inc. Co-founder Meir Eini will step down as chief innovation officer, while remaining an advisor...